Preliminary Program 2022

PRELIMINARY PROGRAM 

Working titles/topics shown. Final titles and speakers will follow.
In person and virtual attendance is available.


EDUCATIONAL SESSIONS

Most of the presentations at SABCS focus on the latest clinical and basic research results relating to breast cancer. By contrast, educational sessions are designed to inform and update those interested in a review on a particular topic. Although these sessions may include new specific research findings, their primary intent is to offer summaries of existing knowledge, and to provide background for some of the active areas which will be discussed in the rest of the meeting.

Digital Health and PROs in Breast Cancer Research and Care
Moderator: Ann H. Partridge, MD, MPH
Dana Farber Institute
Boston, MA

What are PROs and evidence for benefit? 
Shoshana Rosenberg, ScD, MPH
Weill Cornell Medicine
New York, NY

How to incorporate PROs into clinical care
Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA

Where are we going with digital interventions and PROs
Ines Vaz Luis, PhD
Gustave Roussy
Villejuif, France 

Patient Advocate Perspective
Patty Spears, BS
University of North Carolina at Chapel Hill
Chapel Hill, NC

Management of Hereditary Risk: Moderate-Risk Genes and New Approaches
Moderator: Seema A. Khan, MD
Northwestern University
Chicago, IL

Cancer risks in patients with high penetrance gene mutations
Payal D. Shah, MD
Penn Medicine
Philadelphia, PA

Screening for high-risk patients: Does everyone need annual MRI with mammogram?
Madeleine M.A. Tilanus-Linthorst, MD, PhD
Erasmus University Medical Center
Rotterdam, Netherlands

Hormonal exposure and risk in BRCA1/2 carriers
Joanne Kotsopoulos, MSc, PhD
University of Toronto
Toronto, Canada

Antibody Drug Conjugates: Future Directions and Opportunities
Moderator: Ian E. Krop, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Bioengineering and mechanism of action of ADC
Puja Sapra, PhD
AstraZeneca
New York, NY

ADCs in breast oncology: Present and future
Shanu Modi, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Mechanisms of resistance
Leif Ellison, MD, PhD
Massachusetts General Hospital
Boston, MA

Challenging Types of Breast Cancer
Moderator: Bora Lim, MD
Baylor College of Medicine
Houston, TX

Pathologic aspects
Jorge S. Reis-Filho, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Metaplastic
Alexandra Thomas, MD, FACP
Wake Forest Baptist Health
Winston-Salem, NC

Inflammatory
Filipa Lynce, MD
Dana-Farber Cancer Institute
Boston, MA

Lobular/pleomorphic
Sibylle Loibl, MD, PhD
German Breast Group
Neu-isenburg, Germany

Living with Metastatic Breast Cancer
Moderator: Anne Blaes, MD
University of Minnesota
Minneapolis, MN

Early palliative care
Tara L. Kaufmann, MD, MSCE
UT Health Austin
Austin, TX


Support for patients with MBC
Abbey Kaler, MS, APRN, FNP-C
UT MD Anderson Cancer Center
Houston, TX


Financial Toxicity
Fumiko Chino, MD
Memorial Sloan Cancer Center
Boston, MA

Patient Perspective
TBA

Local Therapy - Best Breast Practice
Moderator: TBA

Contralateral mastectomy in patients with germline mutations
Katharine A. Yao, MD
Northshore Medical Group 
Evanston, IL

RT: How short can it be
David Krug, Dr Med
Universitätsklinikum Schleswig-Holstein
Kiel, Germany


How to reconcile novel reconstructive techniques with the need to radiate
Christine Solbach, MD, PhD
University Hospital Frankfurt
Frankfurt, Germany

Spatial and Single Cell Characterization of Breast Cancer Progression 
Moderator: Christina Curtis, PhD, MSc
Stanford University School of Medicine
Stanford, CA

Single cell profiling
TBA

Multiplex spatial proteomic profiling
David Rimm, MD, PhD
Yale University
New Haven, CT

Imaging mass cytometry of breast cancer
Raza Ali, MD, FRCPC, MSc
Cancer Research UK Cambridge Institute
Cambridge, United Kingdom

Beyond the lab: Clinical implications
Christina Curtis, PhD, MSc
Stanford University School of Medicine
Stanford, CA

Targeting the Tumor Microenvironment for Clinical Impact 
Moderator: Diana Cittelly, PhD
University of Colorado Anschutz Medical Campus
Aurora, CO

Influence of bone microenvironment on metastasis
Igor Bado, PhD
Baylor College of Medicine
Houston, TX

The contribution of the tumor microenvironment to cancer dormancy
J. Javier Bravo-Cordero, PhD
Icahn School of Medicine at Mount Sinai
New York, NY

Effects of age on the tumor microenvironment
Sandra S. McAllister, PhD
Harvard Institutes of Medicine
Boston, MA

Can inflammation be targeted?
Angela DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA

What ctDNA Can Tell Us
Moderator: Nicholas Turner, PhD, FRCP
The Royal Marsden Hospital
London, United Kingdom

Which is the best technique
Heather Parsons, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Can ctDNA substitute tissue testing
Ben O'Leary, MBBS, PhD
The Institute of Cancer Research
London, United Kingdom

Using ctDNA in detecting disease
Minetta C. Liu, MD
Mayo Clinic
Rochester, MN

State of the Art Radiotherapy: Reducing Toxicity and Increasing Options
Moderator: Wendy Woodward, MD, PhD
UT MD Anderson Cancer Center
Houston, TX

The role of advanced radiation technology in reducing toxicity
Rachel Jimenez, MD
Massachusetts General Hospital
Boston, MA

Overview of the current state of the art - what patients and oncologists need to know
Melissa Mitchell, MD, PhD
UT MD Anderson Cancer Center
Houston, TX

Evidence for ablative radiation in metastatic breast cancer
Chiaojung Jillian Tsai, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Predictive Value of Treatment Response and Residual Disease After Neoadjuvant Therapy
Virginia Kaklamani, MD
UT Health San Antonio
San Antonio, TX

ER therapies
Cynthia X. Ma, MD, PhD
Washington University in St. Louis
St. Louis, MO

HER2
Luca Gianni, MD
Fondazione Michelangelo
Milano, Italy

Triple negative
Peter Schmid, MD, PhD
Bart's Cancer Institute
London, United Kingdom

New Agents Targeting HRD in Breast Cancer
Moderator: Erica Stringer-Reasor, MD
University of Alabama at Birmingham
Birmingham, AL

Pol-theta inhibitors in HRD tumors
Alan D. d'Andrea, MD
Dana-Farber Cancer Institute
Boston, MA

Mechanisms of sensitivity and resistance to HRD targeting agents in breast cancer – PARPi and beyond
Christopher Lord, D.Phil
Institute of Cancer Research
London, United Kingdom

ATR inhibitors and PARP1 selective PARP inhibitors
Andrew Tutt, MD ChB, MRCP, FRCR, PhD
Institute of Cancer Research
London, United Kingdom

Breast Cancer and Cardiovascular Toxicity: What an Oncologist Needs to Know
Co-Moderator: Carmen Bergom, MD, PhD
Washington University in St. Louis
St. Louis, MO
Co-Moderator: Susan Dent, MD
Duke
Durham, NC

Beyond anthracyclines and trastuzumab: Cardiotoxicity of new novel agents
Susan Dent, MD
Duke
Durham, NC

Radiation therapy and cardiovascular disease in breast cancer
Carmen Bergom, MD, PhD
Washington University in St. Louis
St. Louis, MO

Cardiovascular toxicity and breast cancer: Detection and prevention strategies
TBA

Cardiac problems secondary to chemotherapy
TBA

Top

 



 

William L. McGuire Memorial Lecture

AACR Distinguished Lectureship in Breast Cancer Research

AACR Outstanding Investigator Award for Breast Cancer Research, funded by the Breast Cancer Research Foundation

Susan G. Komen® Brinker Awards

Top



Lineage-defined Metabolism of Normal Mammary Cells and Origins of Cancer Metabolic
TBA

Premenopausal ER+ Breast Cancer: Past, Present, and Future
Prudence Francis, MD
Peter MacCallum Cancer Centre
Victoria, Australia

Top




ER HER2 Crosstalk
Moderator: Carlos Arteaga, MD
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, TX

HER2 signaling the ER cistrome
TBA

Oncogene signal transduction and antiestrogen resistance
Rachel Schiff, PhD
Baylor College of Medicine
Houston, TX

Treatment of ER+/HER2+ breast cancer
TBA

Late Recurrence and Tumor Dormancy
Moderator: Alana Welm, PhD
Masonic Cancer Center
University of Minnesota
Minneapolis, MN

NK cell induced dormancy
Ana Luisa Correia, PhD
Champalimaud Research
Lisboa, Portugal

Extra cellular matrix and dormancy
Javier Bravo-Cordero, PhD
Icahn School of Medicine
New York, NY

Implications for clinical care
Alexandra Thomas, MD, FACP
Wake Forest School of Medicine
Winston-Salem, NC

Top

 

 

 

 

 


Saturday, December 10, 2022

Co-Moderator: Carlos Arteaga, MD
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
San Antonio, TX

Co-Moderator: Virginia Kaklamani, MD
UT Health San Antonio
San Antonio, TX

Basic science
Andrei Goga, MD, PhD
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Translational research
Shom Goel, MBBS, B Med Sci (Hons)
Peter MacCallum Cancer Centre
Melbourne, Australia

Early breast cancer   
Marleen Kok, MD, PhD
Netherlands Cancer Institute
Amsterdam, Netherlands

Advanced breast cancer
Melinda Telli, MD
Stanford University School of Medicine
San Francisco, CA

Top
 

SPECIAL SESSIONS


Tackling the Big Questions in Breast Cancer?
Chairs: 

Carlos Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX

Angela DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA

Panelists:

Fabrice André, MD, PhD
Gustave Roussy
Villejuif, France

Regina Barzilay, PhD
Massachusetts Institute of Technology
Cambridge, MA

Joan S. Brugge, PhD
Harvard Ludwig Cancer Center
Boston, MA

Matthew J. Ellis, MB, BChir, BSc, PhD, FRCP
AstraZeneca
Washington, DC

Yeon Hee Park, MD, PhD
Samsung Medical Center
Seoul, Korea

Lori Pierce, MD
University of Michigan
Ann Arbor, MI

Patty Spears, BS
University of North Carolina at Chapel Hill
Raleigh, NC

Eric Winer, MD
Yale Cancer Center
New Haven, CT

Nadia Harbeck, MD, PhD
University of Munich
Munich, Germany

Diversity

Co-Chairs: 

Thelma Brown, BSc
University of Alabama at Birmingham
Birmingham, AL

Charles Perou, PhD
University of North Carolina
Chapel Hill, NC

Patty Spears, BS
University of North Carolina at Chapel Hill
Raleigh, NC

Top
 

FORUMS


Molecular Aspects of DCIS Progression
Moderator: E. Shelley Hwang, MD, MPH
Duke University
Durham, NC

Tumor stroma in DCIS progression
Robert West, MD, PhD
Stanford University Medical Center
Stanford, CA

Clonal evolution of DCIS to invasion
Jelle Wesseling, MD, PhD
Netherlands Cancer Institute
Amsterdam, Netherlands

Defining clinical risk how do we tailor therapy (using genomic tools/comet)
Kimberly J. Van Zee, MS, MD, FACS
Memorial Sloan Kettering Cancer Center
New York, NY

Modifying Tumor Response: Microbiome, Diet, and Fasting 
Moderator: Sangeetha Reddy, MD, MSc
UT Southwestern Medical Center
Dallas, TX

Fungal regulation of breast tumor radiation response
Stephen L. Shiao, MD, PhD
Cedars-Sinai
Los Angeles, CA

Microbiome and response to immunotherapy
Jennifer A. Wargo, MD
UT MD Anderson Cancer Center
Houston, TX

Fasting and Microbiotic
Guido Kroemer, MD, PhD, PU-PH
University of Paris Descartes
Paris, France

New Targets and Strategies for Immunotherapy
Moderator: Justin Balko, PhD, PharmD
Vanderbilt University Medical Center
Nashville, TN

Activating a collaborative innate-adaptive immune response to control metastasis
Mikala Egeblad, PhD
Cold Spring Harbor Laboratory
New York, NY 

Neutrophil elastase and anti-tumor effects
Lev Becker, PhD
The University of Chicago
Chicago, IL

Immunosuppressive macrophages and PARP inhibitor resistance
Jennifer Guerriero, PhD
Dana-Fraber Cancer Institute
Boston, MA

Demystifying CDKs in Breast Cancer: Beyond CDK4/6
Moderator: Rinath Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA

CDK4/6 inhibitor resistance: Biological mechanisms and novel approaches
Ariella Hanker, PhD
UT Southwestern Medical Center
Dallas, TX

Current status of CDK2 inhibitors in (pre-)clinical development
Sarat Chandarlapaty, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Inhibiting transcriptional CDKs in breast cancer
Charles Coombes, MD, PhD
Imperial College
London, United Kingdom

Top



Clinical Research Workshop

Moderator: Aditya Bardia, MD, MPH
Massachusetts General Hospital
Boston, MA

Use of the postneoadjuvant setting to accelerate drug development
Melinda Telli, MD
Stanford University School of Medicine
San Francisco, CA

How to measure and improve drug adherence in clinical trials
Dawn L. Hershman, MD
Columbia University
New York, NY

Statistical considerations for precision medicine
Nabihah Tayob, PhD
Dana-Farber Cancer Institute
Boston, MA

Bringing trials to all patients: A patient's perspective
Thelma Brown, BSc
University of Alabama at Birmingham
Birmingham, AL

Basic Science Workshop

Moderator: Alana L. Welm, PhD
University of Utah
Salt Lake City, UT

APOBEC and genome evolution in mBC
Reuben S. Harris, PhD
UT Health San Antonio
San Antonio, TX

Therapy-induced senescence: Friend or foe?
Sheila Stewart, PhD
Washington University School of Medicine
St. Louis, MO

Drug-tolerant persister cells in cancer
Joan S. Brugge, PhD
Harvard Ludwig Cancer Center
Boston, MA

Clinical implications of tumor heterogeneity single cell genomics
Nnennaya Kanu, PhD
University College London
London, United Kingdom

Top


DISCUSSIONS

                                                                                                                       

CASE DISCUSSION SESSION

Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX

Panelists:
Michael Gnant, MD, FACS, FEBShon
Medical University of Vienna
Vienna, Austria

Celina Kleer, MD
University of Michigan Medical School
Ann Arbor, MI

Julia Maues
GRASP
Washington, DC

George Sledge, Jr, MD
Stanford University
Stanford, CA

Jonathan Strauss, MD
Northwestern
Chicago, IL

Shaveta Vinayak, MD
 
University of Washington
Seattle, WA  

MOLECULAR TUMOR BOARD
Moderator: Giuseppe Curigliano, MD, PhD
European Institute of Oncology
Milano, Italy

Philippe Aftimos, MD
Institut Jules Bordet
Brussels, Belgium

Philippe Bedard, MD
Princess Margaret Cancer Centre
Toronto, Canada

Amy L. Delson
University of California San Francisco
Atherton, CA

Erika Hamilton, MD
Sarah Cannon Research Institute
Nashville, TN

Sara Hurvitz, MD, FACP
University of California San Francisco
Los Angeles, CA

Aleix Prat, MD, PhD
Hospital Clínic Barcelona
Barcelona, Spain

 

Daniel Stover, MD
Ohio State University Comprehensive Cancer Center
Columbus, OH   

                                                                                                         



CAREER DEVELOPMENT FORUM: NETWORKING SESSION FOR YOUNG INVESTIGATORS

                                                                                                                       

The session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students and residents, who are registered attendees of the 2022 SABCS. Space in the workshop is limited. Preregistration is not required.                                                                                                                             

Top


Clinical Controversies
Moderator: Lisa Carey, MD, ScM, FASCO
UNC-Lineberger Comprehensive Cancer Center
Chapel Hill, NC

To clip or not to clip
Abigail Caudle, MD
UT MD Anderson Cancer Center
Houston, TX
and
Viviana E. Galimberti, MD, MPH
European Institute of Oncology 
Milan, Italy

Duration of endocrine therapy
Kathryn Ruddy, MD, PhD
Mayo Clinic
Rochester, MN
and
Eleftherios (Terry) Mamounas, MD, MSc
Orlando Health Cancer Institute
Orlando, FL

Post Neoadjuvant therapy in TNBC
Heather McArthur, MD, MPH
UT Southwestern
Dallas, TX
and
Susan Domchek, MD
University of Pennsylvania School of Medicine
Philadelphia, PA

Translational Controversies
Moderator: Komal Jhaveri, MD, FACP
Memorial Sloan Kettering Cancer Center
New York, NY

RIP MTD
Hope S. Rugo, MD, FASCO
University of California San Francisco
San Francisco, CA
Geoffrey Shapiro, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Randomized trials vs real world evidence
Angela DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA
Sean Khozin, MD, MPH
CancerLinQ, LLC
New York, NY

Ki 67
Nadia Harbeck, MD, PhD
LMU University Hospital
Munich, Germany
Torsten Nielsen, MD, PhD, FRCPC
University of British Columbia
Vancouver, Canada

 

 

Co-Moderator: Andrea Barrio, MD
Co-Moderator: Sara Tolaney, MD, MPH

Panel Members

Vernal Branch
Patient Advocate
UNC Chapel Hill Lineberger Cancer Institute
Mooresville, NC

Mariana Chavez MacGregor, MD, MSC, FASCO
UT MD Anderson Cancer Center
Houston, TX

Tanja N. Fehm, MD
University Hospital Düsseldorf
Düsseldorf, Germany

Kalliopi Siziopikou, MD, PhD
Northwestern University
Chicago, IL

Mediget Teshome, MD, MPH, FACS
UT MD Anderson Cancer Center
Houston, TX

Cynthia Villarreal-Garza, MD, DSc
Tecnológico de Monterrey
Monterrey, Mexico

Richard C. Zellars, MD
Indiana University
Indianapolis, IN

 

 PRELIMINARY SCHEDULE

Hours subject to change

 

Monday, December 5 Registration  12:00 PM - 5:00 PM 
Tuesday, December 6 Registration  8:00 AM - 5:15 PM ;
  Program  9:00 AM - 6:15 PM 
Wednesday, December 7 Registration  6:45 AM - 5:15 PM 
  Program  7:00 AM - 6:15 PM 
  Exhibits  10:00 AM - 5:00 PM 
Thursday, December 8 Registration  6:45 AM - 5:15 PM 
  Program  7:00 AM - 6:15 PM 
  Exhibits  10:00 AM - 5:00 PM 
Friday, December 9  Registration  6:45 AM - 4:00 PM 
  Program  7:00 AM - 7:00 PM 
  Exhibits  10:00 AM - 5:00 PM 
Saturday, December 10 Registration  7:30 AM - 9:00 AM 
  Program  8:00 AM - 10:00 AM 

Top